

TABLE OF CONTENTS

FLUIDS, ELECTROLYTES, AND NUTRITION	1
<i>Composition of Body Fluids; Types of Intravenous Fluid; Maintenance Fluids and Electrolytes; Dehydration; Sodium Homeostasis; Nutrition Assessment; Caloric Requirements; Enteral Nutrition; Parenteral Nutrition: Delivery of Nutrition Directly into the Bloodstream Through Venous Catheters; Safety Considerations/Complications of Parenteral Nutrition; Failure to Thrive</i>	
ENDOCRINE AND METABOLIC DISORDERS	37
<i>Diabetes Mellitus; Obesity; Hyperthyroidism; Hypothyroidism; Syndrome of Inappropriate Antidiuretic Hormone; Adrenal Insufficiency; Diabetes Insipidus; Phenylketonuria</i>	
GASTROENTEROLOGY	73
<i>Gastroesophageal Reflux Disease; Diarrhea; Constipation; Irritable Bowel Syndrome; Inflammatory Bowel Disease; Short Bowel Syndrome; Appendicitis; Nausea and Vomiting; Ulcers</i>	
PEDIATRIC NEPHROLOGY	163
<i>Nephrotic Syndrome; Hydronephrosis; Renal Tubular Acidosis; Dialysis; Hemolytic Uremic Syndrome</i>	
INFECTIOUS DISEASES	235
<i>Lower Respiratory Tract Infections; Upper Respiratory Tract Infections; Acute Otitis Media; Skin and Soft Tissue Infections; Bone and Joint Infections; Central Nervous System Infections; Urinary Tract Infections; Catheter-Related Bloodstream Infections; Endocarditis; Intra-abdominal Infections; Fungal Infections; Parasitic Infections; Sepsis/Septic Shock; Tuberculosis; Sexually Transmitted Diseases; Surgical Prophylaxis</i>	
IMMUNOLOGY.	293
<i>Eczema/Atopic Dermatitis; Juvenile Idiopathic Arthritis; Severe Combined Immunodeficiency; Vaccinations; Anaphylaxis; Food Allergies; Acute Rheumatic Fever and Rheumatic Heart Disease; Systemic Lupus Erythematosus; Human Immunodeficiency Virus</i>	
PICU I	367
<i>Shock; Sedation/Analgesia/Neuromuscular Blockade; Extracorporeal Membrane Oxygenation (ECMO); Cardiac Arrest; Traumatic Brain Injury; Burns</i>	
PICU II	401
<i>Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State; Status Epilepticus; Acute Respiratory Distress Syndrome; Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia; Stress-Related Mucosal Disease and Upper Gastrointestinal Bleeding</i>	
NEONATOLOGY.	449
<i>Respiratory Distress Syndrome; Bronchopulmonary Dysplasia; Apnea of Prematurity; Intraventricular Hemorrhage; Patent Ductus Arteriosus; Necrotizing Enterocolitis; Persistent Pulmonary Hypertension of the Newborn; Congenitally Acquired Infections; Neonatal Abstinence Syndrome; Drugs in Pregnancy and Lactation</i>	
TOXICOLOGY	499
<i>Poison Control Center Overview; Legislative Changes; Pediatric Poisonings; General Toxicology; Management of Select Agents; Select Antidotes</i>	

NEUROLOGY/PSYCHIATRY.	533
<i>Migraine/Headache; Seizure Disorders; Cerebral Palsy; Autism Spectrum Disorders; Pediatric Bipolar Disorder; Attention-Deficit/Hyperactivity Disorder; Eating Disorders; Substance Use Disorders</i>	
HEMATOLOGY/ONCOLOGY	597
<i>Introduction to Pediatric Oncology; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Non-Hodgkin Lymphomas; Hodgkin Lymphoma; Central Nervous System Tumors; Neuroblastoma; Wilms Tumor; Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Retinoblastoma; Hematopoietic Stem Cell Transplantation; Supportive Care in Pediatric Oncology; Sickle Cell Disease; Hemophilias</i>	
PEDIATRIC TRANSPLANTATION	657
<i>Organs Transplanted and Survival; Indications for Solid Organ Transplantation; Pretransplant Evaluation; Surgical Solid Organ Transplantation Procedure; T-cell Signaling and Replication; Immunobiology of Solid Organ Transplant Rejection; Types of Rejection; Immunosuppressive Therapy; Corticosteroids; Calcineurin Inhibitors Used for Solid Organ Transplantation; Antiproliferative Agents; Mammalian Target of Rapamycin Inhibitors; Lymphocyte-Depleting Agents; Interleukin-2 Receptor Antagonists; Other Biologic and Novel Agents in Solid Organ Transplantation; Anti-infection; Other Considerations After Transplantation</i>	
CARDIOLOGY.	711
<i>Kawasaki Disease; Congenital Heart Diseases; Pediatric Hypertension; Arrhythmias; Anticoagulation; Pulmonary Hypertension</i>	
PULMONARY	823
<i>Asthma; Status Asthmaticus; Cystic Fibrosis; Community-Acquired Pneumonia</i>	
BIOSTATISTICS	871
<i>Biostatistics: An Important Practice Tool; Types of Variables/Data; Types of Statistics; Population Distributions; Confidence Intervals; Hypothesis Testing; Choosing a Statistical Test When Comparing Groups; Decision Errors When Comparing Groups; Correlation and Regression; Survival Analysis; Selected Representative Statistical Tests</i>	
STUDY DESIGNS: FUNDAMENTALS AND INTERPRETATION	895
AND RESEARCH TOPICS	
<i>Various Issues in Study Design; Case Reports/Case Series; Observational Study Designs; Incidence; Prevalence; Relative Risk/Risk Ratios and Odds Ratios; Randomized Controlled Trial Design; Other Issues to Consider in Controlled Trials; Controlled Clinical Trials: Analysis; Common Approaches to Analyzing Clinical Trials; Systematic Review/Meta-analysis; Summary Measures of Effect; Reporting Guidelines for Clinical Studies; Pharmacoeconomic Studies; Sensitivity/Specificity/Predictive Values; Institutional Review Board/Human Subjects' Research; Professional Writing: The Publication Process</i>	
PRACTICE MANAGEMENT	929
<i>Pediatric Considerations for Maintenance of Formulary and Development of Medication Use Guidelines or Protocols; Ensuring Adequate Pharmacy Services to Pediatric Patients; Measuring the Quality of Pharmaceutical Care Provided to Pediatric Patients</i>	

ADDITIONAL RESOURCES

INTRODUCTION TO PEDIATRICS 963

The Role of a Pediatric Pharmacist; Classification of Pediatric Patients; Uniqueness of Pediatric Pharmacotherapy; Epidemiology of the Pediatric Population; Growth and Development; Differences in Pediatric Patient Data—Vital Signs, Laboratory Values, and Calculations; Challenges of Medication Adherence; Off-label Medication Use in Pediatric Patients; Medication Safety; Fundamentals of Pediatric Patient Care; The Present and Future of Pediatric Pharmacy Practice

MEDICATION SAFETY 985

Medication Safety Topics

DRUG FORMULATIONS 1003

Need for Extemporaneous Formulations; Most Commonly Prepared Pediatric Extemporaneous Formulations; Options for Meeting Extemporaneous Formulation Needs; Methods of Preparing Different Extemporaneous Formulations; Factors That Affect the Use of Extemporaneous Formulations in Clinical Practice; Efficacy and Safety of Extemporaneous Formulations; Cost; Future Perspectives on Development of Pediatric Drug Formulations

COMMUNICATING WITH CHILDREN, ADOLESCENTS, AND THEIR CAREGIVERS 1017

Communication to Decrease Errors and Improve Adherence; General Communication Principles for Children and Adolescents; Communicating with Parents

PHARMACOKINETICS, PHARMACODYNAMICS, AND PHARMACOGENOMICS 1029

Pharmacokinetics; Pharmacodynamics; Pharmacogenomics; Applied Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics; Age-Associated Differences in Pathophysiology and Disease

PRINCIPLES AND METHODS OF EDUCATING HEALTH CARE PROFESSIONALS 1059

Evidence Supporting Teaching, Precepting, and Learning; Current Educational Frameworks and Guiding Philosophies; Designing Instruction to Achieve Learning Outcomes; Additional Thoughts on Role Modeling and Mentoring; Knowledge and Skill Assessment Techniques

PEDIATRIC PUBLIC HEALTH AND PATIENT ADVOCACY. 1089

Advocacy for the Pediatric Patient Population in Health Care Policy; Importance of Age-Appropriate Dosage Forms, Product Labeling and Pediatric Population Specific Considerations; Minimization of Medication Errors Through Automation and Technology for the Pediatric Patient; Management of Drug Shortages, Advocating for Drug Allocation to the Pediatric Patient; Pediatric Advocacy Through Professional Organizations, Federal Agencies and Accrediting Bodies; Importance and Value of Postdoctoral Pediatric Trained Pharmacy Specialists and Pediatric Clinical Specialists; Drug Warnings and Information Involving the Pediatric Population; Complementary and Alternative Medicine (CAM); Childhood Poisoning; Vaccines; Secondhand Smoke/Environmental Tobacco Smoke (ETS); Bioterrorism; Challenges of Pediatric Pharmacy Practice